131 related articles for article (PubMed ID: 38520847)
1. Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.
Watanabe S; Yoshioka H; Sakai H; Hotta K; Takenoyama M; Yamada K; Sugawara S; Takiguchi Y; Hosomi Y; Tomii K; Niho S; Nishio M; Kato T; Takahashi T; Ebi H; Aono M; Yamamoto N; Ohe Y; Nakagawa K
ESMO Open; 2024 Apr; 9(4):102975. PubMed ID: 38520847
[TBL] [Abstract][Full Text] [Related]
2. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
Paz-Ares L; Socinski MA; Shahidi J; Hozak RR; Soldatenkova V; Kurek R; Varella-Garcia M; Thatcher N; Hirsch FR
Ann Oncol; 2016 Aug; 27(8):1573-9. PubMed ID: 27207107
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Ciuleanu T; Socinski MA; Obasaju C; Luft AV; Szczesna A; Szafrański W; Ramlau R; Bálint B; Molinier O; Depenbrock H; Nanda S; Paz-Ares L; Thatcher N
Clin Lung Cancer; 2018 Mar; 19(2):130-138.e2. PubMed ID: 29158123
[TBL] [Abstract][Full Text] [Related]
4. Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
Reck M; Thomas M; Kropf-Sanchen C; Mezger J; Socinski MA; Depenbrock H; Soldatenkova V; Brown J; Krause T; Thatcher N
Oncol Res Treat; 2016; 39(9):539-47. PubMed ID: 27614872
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
Park K; Cho EK; Bello M; Ahn MJ; Thongprasert S; Song EK; Soldatenkova V; Depenbrock H; Puri T; Orlando M
Cancer Res Treat; 2017 Oct; 49(4):937-946. PubMed ID: 28111429
[TBL] [Abstract][Full Text] [Related]
6. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
7. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
Reck M; Socinski MA; Luft A; Szczęsna A; Dediu M; Ramlau R; Losonczy G; Molinier O; Schumann C; Gralla RJ; Bonomi P; Brown J; Soldatenkova V; Chouaki N; Obasaju C; Peterson P; Thatcher N
J Thorac Oncol; 2016 Jun; 11(6):808-18. PubMed ID: 26980471
[TBL] [Abstract][Full Text] [Related]
9. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
Watanabe S; Yoshioka H; Sakai H; Hotta K; Takenoyama M; Yamada K; Sugawara S; Takiguchi Y; Hosomi Y; Tomii K; Niho S; Yamamoto N; Nishio M; Ohe Y; Kato T; Takahashi T; Kamada A; Suzukawa K; Omori Y; Enatsu S; Nakagawa K; Tamura T
Lung Cancer; 2019 Mar; 129():55-62. PubMed ID: 30797492
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
[TBL] [Abstract][Full Text] [Related]
11. Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer.
DeLozier AM; Brown J; Natanegara F; Zhao L; Cui ZL; Able SL; Bowman L; Treat J; Hess LM
Syst Rev; 2014 Sep; 3():102. PubMed ID: 25227571
[TBL] [Abstract][Full Text] [Related]
12. Necitumumab for the treatment of advanced non-small-cell lung cancer.
Díaz-Serrano A; Sánchez-Torre A; Paz-Ares L
Future Oncol; 2019 Mar; 15(7):705-716. PubMed ID: 30501503
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
Besse B; Barlesi F; Demedts I; Fuentes Pradera J; Robinet G; Gazzah A; Soldatenkova V; Frimodt-Moller B; Kim JS; Vansteenkiste J
Lung Cancer; 2019 Nov; 137():136-143. PubMed ID: 31586771
[TBL] [Abstract][Full Text] [Related]
15. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
16. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
18. Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.
di Noia V; D'Argento E; Pilotto S; Grizzi G; Caccese M; Iacovelli R; Tortora G; Bria E
Expert Opin Biol Ther; 2018 Sep; 18(9):937-945. PubMed ID: 30075697
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
